GATA6 and neoplasm: Moreover, GATA6-low or basal-like tumours were found to be less responsive to FFX, and thus, have the potential to serve as a predictive biomarker of a therapeutic response, which is being prospectively evaluated in the Pancreatic Adenocarcinoma Signature Stratification for Treatment (PASS-01) trial (NCT04469556) [47,48,50,55].